AKTX

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Akari Therapeutics PLC

NASDAQ | AKTX

0.34

USD

$0.00

(

0.00%

)

At Close (As of Dec 3, 2025)

$16.96M

Market Cap

0

P/E Ratio

0

EPS

$1.73

52 Week High

$0.31

52 Week Low

HEALTHCARE

Sector

AKTX Chart

Recent Chart
Price Action

AKTX Technicals

Tags:

AKTX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$14K
Total Revenue $0
Cost Of Revenue $14K
Costof Goods And Services Sold $14K
Operating Income -$22M
Selling General And Administrative $9.7M
Research And Development $7M
Operating Expenses $22M
Investment Income Net -
Net Interest Income -$236K
Interest Income $8K
Interest Expense $244K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $14K
Income Before Tax -$20M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$20M
Comprehensive Income Net Of Tax -
Ebit -$20M
Ebitda -$20M
Net Income -$20M

Revenue & Profitability

Earnings Performance

AKTX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $51M
Total Current Assets $3M
Cash And Cash Equivalents At Carrying Value $2.6M
Cash And Short Term Investments $2.6M
Inventory -
Current Net Receivables $201K
Total Non Current Assets $48M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $39M
Intangible Assets Excluding Goodwill $39M
Goodwill $8.4M
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $152K
Other Non Current Assets -
Total Liabilities $28M
Total Current Liabilities $20M
Current Accounts Payable $12M
Deferred Revenue -
Current Debt -
Short Term Debt $3.3M
Total Non Current Liabilities $8.4M
Capital Lease Obligations -
Long Term Debt -
Current Long Term Debt $3.3M
Long Term Debt Noncurrent -
Short Long Term Debt Total $3.3M
Other Current Liabilities $4.2M
Other Non Current Liabilities $383K
Total Shareholder Equity $22M
Treasury Stock -
Retained Earnings -$247M
Common Stock $5.3M
Common Stock Shares Outstanding $12K

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$13M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $14K
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $382K
Cashflow From Financing $11M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$20M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$14K
Total Revenue $0
Cost Of Revenue $14K
Costof Goods And Services Sold $14K
Operating Income -$22M
Selling General And Administrative $9.7M
Research And Development $7M
Operating Expenses $22M
Investment Income Net -
Net Interest Income -$236K
Interest Income $8K
Interest Expense $244K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $14K
Income Before Tax -$20M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$20M
Comprehensive Income Net Of Tax -
Ebit -$20M
Ebitda -$20M
Net Income -$20M

AKTX News

AKTX Profile

Akari Therapeutics PLC Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Akari Therapeutics PLC is a London-based clinical-stage biopharmaceutical company dedicated to developing innovative therapies for autoinflammatory diseases by targeting the complement and leukotriene pathways. The company boasts a diverse pipeline of drug candidates aimed at addressing significant unmet medical needs and enhancing patient outcomes. With a commitment to leveraging its scientific expertise through strategic partnerships, Akari Therapeutics is well-positioned to effectively navigate the complexities of clinical development and deliver transformative therapies to market.

LPTX
+368.57%
$2.05
PAVS
-38.29%
$0.03
VRAX
+75.10%
$0.68
IRBT
+73.84%
$3.39
IXHL
+12.68%
$0.44
NVDA
-1.03%
$179.59
PLRZ
+131.96%
$7.33
KITT
+115.88%
$1.56
VHAI
0.00%
$0.00
TWOH
0.00%
$0.00
PLUG
+5.68%
$2.22
NIO
-4.97%
$4.78
ONDS
+6.46%
$8.07
RR
+18.53%
$4.22
INTC
+0.66%
$43.76
IPG
-1.95%
$24.57
ASST
+0.96%
$1.04
BYND
-3.10%
$1.25
VALE
+3.25%
$13.31
BITF
-0.08%
$3.09
TSLA
-0.20%
$429.24
AXDX
-61.36%
$0.03
AAL
+2.24%
$14.56
IREN
+6.90%
$43.96
BBD
+1.38%
$3.67
CAPR
+371.06%
$29.96
BMNR
+5.20%
$33.57
QCLS
+38.16%
$4.67
SOFI
-1.49%
$29.07
PFE
+1.84%
$25.61
ADAP
-15.14%
$0.05
MRVL
+7.15%
$99.54
DNN
+2.77%
$2.59
INHD
-6.65%
$0.13
NFLX
-5.05%
$103.82
AAPL
-0.71%
$284.15
SOND
-23.45%
$0.12
MARA
+4.70%
$12.47
ACHR
+8.43%
$8.29
BMNU
+9.94%
$8.07
F
+1.15%
$13.11
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
IVP
-0.62%
$0.12
ITUB
+2.64%
$7.89
BAC
+1.67%
$54.08
BTBT
+4.01%
$2.33
AMZN
-0.87%
$232.38
SRM
+53.27%
$10.30
GRAB
-0.18%
$5.26
AEO
+15.17%
$23.99
MSFT
-2.50%
$477.73
EXK
-1.70%
$9.24
PCG
-0.58%
$15.23
RIG
+3.13%
$4.44
CIFR
+5.61%
$18.63
CLSK
+5.30%
$14.43
T
-1.04%
$25.52
QBTS
+10.75%
$24.92
RIVN
+1.74%
$17.53
KVUE
+0.11%
$16.88
PLTR
+3.15%
$176.08
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
RGTI
+9.08%
$26.05
PLTD
-2.65%
$6.77
BMY
+5.66%
$50.98
MSTR
+3.89%
$188.39
BTG
+1.24%
$4.48
WULF
+0.40%
$14.27
GOOG
+0.28%
$316.02
GOOGL
+1.63%
$320.97
WMT
+1.81%
$114.45
HOOD
+6.10%
$133.64
AMD
+0.76%
$216.88
ASBP
-10.81%
$0.08
CHR
-6.96%
$0.04
AFMD
-34.94%
$0.18
NOK
+1.05%
$6.25
MCHP
+12.16%
$63.61
WBD
+0.16%
$24.57
IMRN
-10.91%
$1.55
CMG
-0.55%
$33.95
HBAN
+2.65%
$17.00
M
-1.10%
$22.46
PMAX
+26.43%
$2.87
PSTG
-27.29%
$68.87
DRCT
-15.28%
$0.10
CMND
-12.73%
$0.11
GTLB
-12.06%
$38.13
AMCR
+0.77%
$8.46
CGC
+4.95%
$1.16
VZ
+0.22%
$40.70
RXRX
+7.87%
$4.66
SNAP
+0.20%
$7.63
SMR
+4.59%
$18.91
GRYP
-10.38%
$1.38
VIVK
-13.89%
$0.09
ORCL
+3.32%
$207.78
LPTX
+368.57%
$2.05
PAVS
-38.29%
$0.03
VRAX
+75.10%
$0.68
IRBT
+73.84%
$3.39
IXHL
+12.68%
$0.44
NVDA
-1.03%
$179.59
PLRZ
+131.96%
$7.33
KITT
+115.88%
$1.56
VHAI
0.00%
$0.00
TWOH
0.00%
$0.00
PLUG
+5.68%
$2.22
NIO
-4.97%
$4.78
ONDS
+6.46%
$8.07
RR
+18.53%
$4.22
INTC
+0.66%
$43.76
IPG
-1.95%
$24.57
ASST
+0.96%
$1.04
BYND
-3.10%
$1.25
VALE
+3.25%
$13.31
BITF
-0.08%
$3.09
TSLA
-0.20%
$429.24
AXDX
-61.36%
$0.03
AAL
+2.24%
$14.56
IREN
+6.90%
$43.96
BBD
+1.38%
$3.67
CAPR
+371.06%
$29.96
BMNR
+5.20%
$33.57
QCLS
+38.16%
$4.67
SOFI
-1.49%
$29.07
PFE
+1.84%
$25.61
ADAP
-15.14%
$0.05
MRVL
+7.15%
$99.54
DNN
+2.77%
$2.59
INHD
-6.65%
$0.13
NFLX
-5.05%
$103.82
AAPL
-0.71%
$284.15
SOND
-23.45%
$0.12
MARA
+4.70%
$12.47
ACHR
+8.43%
$8.29
BMNU
+9.94%
$8.07
F
+1.15%
$13.11
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
IVP
-0.62%
$0.12
ITUB
+2.64%
$7.89
BAC
+1.67%
$54.08
BTBT
+4.01%
$2.33
AMZN
-0.87%
$232.38
SRM
+53.27%
$10.30
GRAB
-0.18%
$5.26
AEO
+15.17%
$23.99
MSFT
-2.50%
$477.73
EXK
-1.70%
$9.24
PCG
-0.58%
$15.23
RIG
+3.13%
$4.44
CIFR
+5.61%
$18.63
CLSK
+5.30%
$14.43
T
-1.04%
$25.52
QBTS
+10.75%
$24.92
RIVN
+1.74%
$17.53
KVUE
+0.11%
$16.88
PLTR
+3.15%
$176.08
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
RGTI
+9.08%
$26.05
PLTD
-2.65%
$6.77
BMY
+5.66%
$50.98
MSTR
+3.89%
$188.39
BTG
+1.24%
$4.48
WULF
+0.40%
$14.27
GOOG
+0.28%
$316.02
GOOGL
+1.63%
$320.97
WMT
+1.81%
$114.45
HOOD
+6.10%
$133.64
AMD
+0.76%
$216.88
ASBP
-10.81%
$0.08
CHR
-6.96%
$0.04
AFMD
-34.94%
$0.18
NOK
+1.05%
$6.25
MCHP
+12.16%
$63.61
WBD
+0.16%
$24.57
IMRN
-10.91%
$1.55
CMG
-0.55%
$33.95
HBAN
+2.65%
$17.00
M
-1.10%
$22.46
PMAX
+26.43%
$2.87
PSTG
-27.29%
$68.87
DRCT
-15.28%
$0.10
CMND
-12.73%
$0.11
GTLB
-12.06%
$38.13
AMCR
+0.77%
$8.46
CGC
+4.95%
$1.16
VZ
+0.22%
$40.70
RXRX
+7.87%
$4.66
SNAP
+0.20%
$7.63
SMR
+4.59%
$18.91
GRYP
-10.38%
$1.38
VIVK
-13.89%
$0.09
ORCL
+3.32%
$207.78
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.